IV. Capsaicin Metabolism
Capsaicin metabolism after oral administration is believed to be similar in the human, rat, and canine microsome. When capsaicin and dihydrocapsaicin reaches the liver, a major part is metabolized; however, the proportion that undergoes metabolism is unclear. In vitro experiments show that the amount of capsaicin and dihydrocapsaicin is greatly reduced after incubation with liver homogenates (Donnerer et al., 1990; Chanda et al., 2008). In situ experiments in rats have shown that the intestinal elimination rate of capsaicin and dihydrocapsaicin is approximately equal to the concentration of radioactivity in mesenteric venous blood, indicating that presumably no metabolism take place in the gut lumen (Kawada et al., 1984).
An in vitro human investigation with hepatic microsomes and S9 fractions (used to investigate involvement of phase 2 metabolisms), showed that capsaicin was rapidly metabolized, producing three major metabolites, 16-hydroxycapsaicin, 17-hydroxycapsaicin, and 16,17-hydroxycapsaicin, whereas vanillin was a minor metabolite (Chanda et al., 2008). Moreover, Chanda et al. (2008) established a model to elucidate the metabolism of capsaicin at various concentrations physiologically equivalent to those obtained after oral ingestion of pepper fruits. They showed that capsaicin metabolism was less extensive at a concentration of 10 μM than at 1 μM (more than 50% direct inhibition of CYP1A2, CYP2C9, and CYP2C19), and the authors suggest therefore that the rate of metabolism is saturable. Although many enzymes may play some role in hepatic drug metabolism, cytochrome P450 (P450) enzymes are quantitatively the most important, and many drug-drug interactions result from the alteration (increase or decrease) in the activities of these enzymes. At the much lower plasma capsaicin concentrations occurring after topical administration, such as via the 8% patch, direct inhibition of any P450 enzyme has not been shown. Because inhibition of CYP2E1 is thought to prevent the metabolic activation of several carcinogens, and because capsaicin is believed to possess anticancer properties, it has been widely inferred that capsaicin is a CYP2E1 inhibitor. This implication, however, appears in only one publication (Reilly and Yost, 2006). There is no information on the ability of any of these compounds to modulate P450 activity and, to the best of our knowledge, the actions of the metabolites 16-hydroxycapsaicin and 17-hydroxycapsaicin are not known.
In vitro studies of capsaicin in human skin have shown slow biotransformation, and most capsaicin remains unchanged; only a small fraction is metabolized to vanillylamine and vanillyl acid (Chanda et al., 2008). This suggests that cytochrome P450 enzymes participate minimally in capsaicin transformation in skin compared with their key role in hepatic metabolism.
Go to:
V. Capsaicin Elimination
Animal studies have shown that capsaicin is eliminated mainly by the kidneys, with a small untransformed proportion excreted in the feces and urine (Leelahuta et al., 1983; Kawada et al., 1984; Surh et al., 1995). It is excreted in both free form and glucuronide form. In vivo animal studies have shown that after 48 h, only a small amount (<10%) of an administered dose was found in feces (Leelahuta et al., 1983; Kawada et al., 1984).